Global Community

MindWalk Holdings Corp. (NASDAQ: HYFT) presents a classic case of market mispricing driven by a transitional lag.Read more

This mining company’s outlook changes fast if gold and silver prices rise and it hits its production and cost targets. See how a ramp-up at its operations, plus debt payoff or new discoveries, could boost cash generation—or how missed guidance could derail it.Read more

A lot of the recent selling in PROCEPT BioRobotics may be more about shifting analyst opinions than real damage to the business, as management pushes back on a widely cited growth concern. If upcoming results confirm procedure demand, the recent slide could reverse quickly—and the company’s new reporting approach may be masking how healthy usage really is.Read more

UUE Holdings lands steady utility and power projects and is pushing into data-centre and fibre buildouts, where demand keeps rising across the region. The twist is that the market still treats it like a slow, risky contractor, even as its work pipeline and profits look like they’re building momentum.Read more

Long-term value investor focused on agriculture and food businesses. I research companies through the lens of ROIC, free cash flow, competitive advantages, and intrinsic value.Read more

The Metaphor Upfront: Investing in DTSQ is like buying a ticket on a lifeboat whose captain has just decided to purchase a luxuriously labeled but barely inspected cargo ship in the middle of the open sea. Those who disembark in time get their money back plus a small interest premium.Read more

What Does Mastercard Do? Most people should already be familiar with this company, but for those who aren't: Mastercard runs the rails connecting banks, merchants, and the billions of cards carrying its brand.Read more

KITZ makes a bold move into the heart of the chipmaking supply chain by buying VTEX, turning it into a serious second-choice supplier for equipment makers that want an alternative to the dominant player. The deal is timed when the industry is coming off a lull, so a rebound in chip-factory spending could make this shift look bigger than the market expects.Read more

A healthcare device maker looks like a steady long-term add for someone trying to spread risk beyond big drug companies, helped by a recent buyout that broadens its brain-related tech offerings. The appeal is slow-and-steady growth and a long history of raising its payout, though the outlook isn’t flashy and some experts sound cautious.Read more